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Abstract
The aim of the present study was to evaluate the anti-inflammatory efficacy of Daclizumab, an anti-interleukin-2 receptor
drug, in an experimental uveitis model upon a subcutaneous injection of lipopolysaccharide into Lewis rats, a valuable
model for ocular acute inflammatory processes. The integrity of the blood-aqueous barrier was assessed 24 h after
endotoxin-induced uveitis by evaluating two parameters: cell count and protein concentration in aqueous humors. The
histopathology of all the ocular structures (cornea, lens, sclera, choroid, retina, uvea, and anterior and posterior chambers)
was also considered. Enzyme-linked immunosorbent assays of the aqueous humor samples were performed to quantify the
levels of the different chemokine and cytokine proteins. Similarly, a biochemical analysis of oxidative stress-related markers
was also assessed. The inflammation observed in the anterior chamber of the eyes when Daclizumab was administered with
endotoxin was largely prevented since the aqueous humor protein concentration substantially lowered concomitantly with
a significant reduction in the uveal and vitreous histopathological grading. Th1 lymphocytes-related cytokines, such as
Interleukin-2 and Interferon-c, also significantly reduced with related anti-oxidant systems recovery. Daclizumab treatment
in endotoxin-induced uveitis reduced Th1 lymphocytes-related cytokines, such as Interleukin-2 and Interferon gamma, by
about 60–70% and presented a preventive role in endotoxin-induced oxidative stress. This antioxidant protective effect of
Daclizumab may be related to several of the observed Daclizumab effects in our study, including IL-6 cytokine regulatory
properties and a substantial concomitant drop in INFc. Concurrently, Daclizumab treatment triggered a significant
reduction in both the uveal histopathological grading and protein concentration in aqueous humors, but not in cellular
infiltration.
Citation: Me´rida S, Sancho-Tello M, Navea A, Almansa I, Muriach M, et al. (2014) An Anti-Interleukin-2 Receptor Drug Attenuates T- Helper 1 Lymphocytes-
Mediated Inflammation in an Acute Model of Endotoxin-Induced Uveitis. PLoS ONE 9(3): e90216. doi:10.1371/journal.pone.0090216
Editor: Carlos Hermenegildo, University of Valencia, Spain
Received November 6, 2013; Accepted January 26, 2014; Published March 3, 2014
Copyright:  2014 Me´rida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported in part by Grant no. PRUCHB06/09 and PRCEU-UCH 13/07 from the Fundacio´n San Pablo to FBM and the Copernicus
Santander Programme of the Universidad CEU Cardenal Herrera. The last corrections of the work (revision process) have been supported by Mutua Madrilen˜a
Institution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fbosch@uch.ceu.es
. These authors contributed equally to this work.
Introduction
Uveitis is an ophthalmological disorder that causes vision loss
and involves several heterogeneous diseases, all characterized by
intraocular inflammation starting firstly in the uvea, whose
differently involved immune pathways remain to be accurately
described [1]. Ocular inflammation mainly involves the uveal tract
but can also extend to other ocular structures such as the retina or
vitreous. There are numerous causes involved, including systemic
autoimmune disorders and infection.
The commonest form of uveitis is acute anterior uveitis (AAU),
which is considered to have a better visual prognosis than other
forms of uveitis; AAU represents up to 92% of all cases of uveitis,
and therefore contributes to visual loss from uveitis [2]. In the past
few years, inflammation has been recognized as a major driving
force of AAU. It is now well-established that, starting from the
initial lesion to the iris and the aqueous humor in the eye,
numerous cellular and molecular inflammatory components
participate in the disease process. Monocyte-derived macrophages
and T-lymphocytes are the predominant invading immune cells
found in evolving lesions. Both cell types produce a wide array of
soluble inflammatory mediators (cytokines and chemokines) that
are critically important in the initiation and perpetuation of the
disease [3].
Uveitis represents a wide spectrum of intraocular inflammatory
conditions and includes various autoimmune and infectious
etiologies. Endotoxin-induced uveitis (EIU) is a useful model of
human anterior uveitis that is not autoimmune. It has served as a
valuable model for ocular acute inflammatory processes driven by
innate immune mechanisms and their effects on the tissue, elicited
by systemic injection of bacterial endotoxin [4]. So, it is an acute
form of uveitis that can be induced by giving rats systemic
injections of a sublethal dose of lipopolysaccharide (LPS), a
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component of the cell walls of Gram-negative bacteria [5]. EIU is
marked by the vasodilatation of the iris and vascular changes in
the ciliary body, accompanied by increased vascular permeability
and a breakdown of the blood-aqueous barrier [6,7]. In the
anterior segment of the eye, it induces a disruption of the blood-
barrier that triggers protein leakage in the anterior chamber by the
infiltration of macrophages and neutrophils into the eye.
Inflammation ensues 4 h after the LPS injection, peaks after 24-
48 h, and declines 96 h after disease induction [1,7].
Wide clinical and experimental evidence support the role of
particular Gram-negative bacteria or their lipopolysaccharides
(LPS) in the pathogenesis of noninfectious, immune-mediated
AAU [7].
In EIU cytokines and chemokines are involved in the response,
but why systemic injection of LPS would cause a response in the
eye, is still not well known [4]. So, in the development and
modulation of this animal model for acute ocular inflammation,
various cytokines and chemokines released by infiltrating cells,
such as TNF-alpha, INF-gamma, TGF-beta, IL-1, IL-6, IL-8,
MCP-1, Rantes and inflammatory mediators are important
[1,8,9]. Moreover in EIU, Th1 activation seems predominant,
but with any kind of Th2 participation [1].
Indeed, in other experimental uveitis models, the inflammatory
mediator expression pattern largely paralleled that seen in Th1-
induced disease [10]. So, experimental autoimmune uveitis disease
induction has been characterized by the polarization of early T-
helper (Th)0 or Th2-like responses towards Th1, whereas
resistance to disease is associated with both regulatory cells and
polarization towards a Th2 pathway [11].
Thus, secretion of cytokines and chemokines, and the LPS
activation of neutrophil and mononuclear cells in ocular tissues,
trigger the release of proteolytic enzymes and free radicals, among
other substances that are related to oxidative stress [12,13].
In the present work, we were interested in the possible effect of
Daclizumab, a humanized mononuclear antibody directed against
high-affinity interleukin-2 (IL-2R), on ocular inflammation, more
precisely in acute anterior uveitis, by using a well-known EIU
model. Daclizumab is a humanized monoclonal antibody of the
IgG1 subtype that binds to the Tac epitope on the interleukin-2
(IL-2) receptor a-chain (CD25) and, effectively blocks the
formation of the high-affinity IL-2 receptor [14]. Interaction of
IL-2 with this receptor is required for the clonal expansion and
continued viability of activated T-cells, which means that so, IL-
2Ra is expressed on activated T cells, but not on resting T-cells or
B-cells, NK cells and monocytes. Indeed, IL-2 is a cytokine
produced by and acting on T-lymphocytes with complex actions.
So, IL-2 augments the immune responses mediated by conven-
tional T-cells [14,15]. On the one hand, CD4+CD25+FoxP3+
regulatory T-cells (Tregs) depend on IL-2, so IL-2 is critical for
peripheral tolerance. On the other hand, IL-2 augments the
immune responses mediated by conventional T-cells [14,15].
Since in 1999 Nussenblatt et al. [16] studied Daclizumab for
treatment of noninfectious intermediate and posterior uveitis, it
has been also studied for the treatment of autoimmune uveitis [17]
and recently, it has been securely and effectively used for the
treatment of intermediate and posterior uveitis in adults [18,19].
Furthermore, high-dose intravenous Daclizumab can help reduce
active inflammation in active Juvenile Idiopathic Arthritis-associ-
ated anterior uveitis, but patients need to be monitored for
potential side effects [20].
Daclizumab has been also shown to be effective in reducing
acute rejection episodes in patients undergoing different solid
organ transplants, including renal [21], lung [22] and pancreatic
[23]. Daclizumab administration has also led to a marked and
prolonged decrease in Tregs in cancer patients, suggesting that
Daclizumab may be an effective and available therapeutic agent
for Tregs modulation in these patients [24].
Thus, the purpose of the present study is to investigate the
efficacy of Daclizumab in an animal model of acute anterior
ocular inflammation that is not autoimmune. We investigated the
effects of Daclizumab on cellular infiltration, protein leakage,
oxidative stress markers, and also on the levels of cytokines and
chemokines in the aqueous humor of rats in an attempt to




Male Lewis rats weighing 250–300 g were used (Harlan Ibe´rica
SL, Barcelona, Spain). All the animal manipulations were carried
out according to European Union (86/608/EEC) and ARVO
(Association for Research in Vision and Ophthalmology) interna-
tional regulations. The study was also approved by the Committee
on the Ethics of Animal Experiments of the Universidad CEU-
Cardenal Herrera (Permit number: 315/2006). Animals were
individually caged and maintained in a 12 h/12 h light/dark
environment of less than 100 cds/m2 illuminance during the light
phase, with controlled temperature (20uC) and relative humidity
(60%), and access to food and water ad libitum.
Animal treatment
Rats were anesthetized with an intraperitoneal injection of
ketamine (100 mg/kg body weight) and azepromazine (2.5 mg/kg
body weight) before any treatment, and were randomly assigned to
four different experimental groups.
Endotoxin-induced uveitis was induced by footpad injections of
200 mg LPS (100 mg each footpad) from Salmonella typhimurium
(Sigma-Aldrich, St. Louis, MO, USA), diluted in 0.2 ml saline.
Control animals received the same amount of saline without LPS
[25].
Immediately after the LPS injection, rats were i.v. injected with
Daclizumab (5 mg/kg body weight) diluted in saline, or the same
amount of saline without Daclizumab. Table 1 summarizes the
different treatments and the number of rats used.
Sacrificing animals
Twenty-four hours after LPS and/or Daclizumab treatment,
rats were anesthetized and sacrificed by cervical dislocation. Then,
the aqueous humor was obtained and enucleation was carried out
immediately. Eyes were either stored in 10% buffered formalde-
hyde for histopathological evaluation or frozen at 280uC until
processed for the biochemical analysis.
Table 1. Summary of treatment groups.
Footpad
injection i.p. injection Treatment group
No. of
animals
Saline Saline Control (C) 13
Saline Daclizumab Daclizumab (D) 13
Endotoxin Saline Endotoxin (E) 18
Endotoxin Daclizumab Endotoxin+Daclizumab (E+D) 15
doi:10.1371/journal.pone.0090216.t001
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Aqueous humor collection and cell counting
Immediately after sacrificing the animals, aqueous humors were
collected from both eyes by an anterior chamber puncture using
an insulin syringe. Approximately, 20 ml/rat were obtained.
The integrity of the blood-aqueous barrier was assessed 24 h
after the uveitis induction by evaluating two parameters: cell count
and protein concentration in aqueous humors. For cell counting,
an aliquot of aqueous humor was diluted in an equal volume of
trypan blue, and cells were counted with a hemocytometer under a
light microscope. The number of viable and non- viable cells per
field (equivalent to 0.1 ml) was manually counted, while the
number of cells per microliter was obtained by averaging the
results of at least four fields from each sample.
After performing the cell count, aqueous humors were
centrifuged at 300xg for 5 min; the cell-free supernatant was
removed and frozen at 280uC until use.
Histopathological evaluation
Eyes were stored in buffered paraformaldehyde for 24–48 h to
be then embedded in paraffin following standard procedures.
Sagittal sections (3-mm thick) were cut near the optic nerve head,
and were stained with hematoxylin and eosin (HE). The
histopathology of all the ocular structures (cornea, lens, sclera,
choroid, retina, uvea, and anterior and posterior chambers) was
evaluated. The histopathological evaluation of inflammation was
scored with grades 0–3, these being: no infiltrating cells (0), mild
(1), moderate (2) or severe (3) cell infiltration.
Biochemical analysis
Lense-less eyes were removed from enucleated eyes given their
high glutathione concentration. On the one hand, Glutathione
(gamma-glutamyl-cysteinyl-glycine, GSH) is the most abundant
low-molecular-weight thiol, and GSH/glutathione disulfide is the
major redox couple in animal cells. On the other hand,
Malondialdehyde (MDH) is one of the most prevalent byproducts
of lipid peroxidation during oxidative stress. So, lense-less eyes
were frozen at 280uC until processed for the biochemical analysis
of oxidative stress markers: malondialdehyde (MDA) and gluta-
thione (GSH) concentrations, glutathione peroxidase (GSH-Px)
activity, and protein concentration.
Eyes were homogenized in 0.2 M potassium phosphate buffer,
pH 7.0, and were frozen at 220uC until use.
The protein concentration was measured according to a
modified method described by Lowry et al. [26,27].
Cytokines and chemokines become redundant secreted proteins
with growth, differentiation, and activation functions that regulate
and determine the nature of immune responses and control
immune cell trafficking and the cellular arrangement of immune
organs. The enzyme-linked immunosorbent assays (ELISA) of the
aqueous humor samples were performed to quantify the levels of
the different chemokine proteins (MIP-1a, MIP-2, MIP-3a,
GRO/KC, RANTES, MCP-1, Fractalkine) and cytokine proteins
(IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, TNFa, INFc, GM-CSF).
ELISAs (Searchlight Multiplex rat Assays; Pierce Biotechnology
Inc., Woburn, MS, USA) were carried out following the
manufacturer’s instructions.
MDA was measured in eye homogenates by high-pressure
liquid chromatography (HPLC, Waters-LC Module I Plus, Waters
Cromatografia, SA, Spain), following the Richard’s procedure
modified by Romero [28,29]. HPLC was done in a Spheryc-5,
ODS 5 mm, 25064.6 mm column (Brownlee-Columns), at a flow
rate of 1 ml/min [29]. Values are expressed as nmol/mg of
protein.
GSH was also measured in eye homogenates by HPLC (Gilson
International B.V. Spain) following the procedure of Reed et al.
[30]. A 3-Spherisorb NH2 5 mm, 25064.6 mm column (Waters
Cromatografia, SA, Spain) was used at a flow rate of 1 ml/min.
Values are expressed as nmol/mg of protein.
Glutathione peroxidase activity was measured spectrophoto-
metrically by monitoring NADPH oxidation at 340 nm, as
described Paglia and Valentine [31]. Values are expressed as
nmol of NADPH oxidized/min/mg of protein.
Statistical analysis
Data are expressed as the mean 6 SE. Comparisons between
groups were made by one-way ANOVA. We performed the
analysis of variance of the data obtained by the Levene test, using
the LSD test as a post hoc test when the data showed homogeneity
in their variances (p,0.05), or a Dunnet T3 test when variances
differed. Statistical differences were set at the p#0.05 level.
No statistically significant differences were found between the
data obtained from the Control and Daclizumab groups for any of
the parameters studied.
Results
Effect of Daclizumab on protein concentration and
cellular infiltration in aqueous humors
Severe inflammation was noted in the rat anterior chamber of
the eye at 24 h post-endotoxin administration, suggesting a
disruption of blood-barrier integrity. Thus, a significant increase
in protein concentration (p#0.05 vs. the C and D groups;
Figure 1A) and in inflammatory cellular infiltration (p#0.05 vs.
the C and D groups; Figure 1B) was observed in the aqueous
humors of endotoxin-treated rats.
Administering Daclizumab along with endotoxin moderately
prevented the inflammation observed in the anterior chamber of
the eyes since a significant reduction was observed in the aqueous
humor protein concentration (p#0.05 vs. the C, D and E groups),
but not in cellular infiltration (p.0.05 vs. the E group; Figure 1A,
B).
Histopathological findings
Uveitis was achieved by endotoxin treatment, as demonstrated
by the significant increase in the number of inflammatory cells in
the uveal tissue (p#0.05 vs. the C and D groups; Figure 1C)
observed in the histopathological sections (Figure 2). The
simultaneous Daclizumab administration largely prevented endo-
toxin-induced uveitis, with a significant reduction noted in the
uveal histopathological grading (p#0.05 vs. the E group).
Endotoxin treatment also brought about a significant increase in
inflammatory cells in the posterior chamber (p#0.05 vs. the C and
D groups; Figure 1D), although it was less severe than in the uveal
tissue. Similarly, the simultaneous administration of Daclizumab
and endotoxin largely prevented endotoxin-induced vitreous
inflammation (p#0.05 vs. the E group).
Retinal tissue showed no morphological alterations at 24 h post-
systemic endotoxin administration, and no other histopathological
alteration was observed in the other ocular tissues (cornea, lens,
choroid, or optic nerve) in any of the groups studied.
Daclizumab prevents endotoxin-induced oxidative stress
Different parameters relating to oxidative stress were measured
in the eye homogenates from rats 24 h after endotoxin and/or
Daclizumab treatment. Endotoxin led to a significant reduction in
anti-oxidant systems, such as GSH peroxidase and GSH (p#0.05
vs. the C and D groups; Figures 3A, B), which fully recovered by a
Daclizumab in Experimental Uveitis
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Figure 1. Effect of Daclizumab on protein concentration (A) and cellular infiltration (B) in the aqueous humor collected 24 h after
endotoxin treatment, and on the histopathological score of uveal (C) and vitreous (D) cellular infiltration. Each value represents the
mean 6 SE. *p#0.05 vs. the Control and Daclizumab groups and #p#0.05 vs. the Endotoxin group.
doi:10.1371/journal.pone.0090216.g001
Figure 2. Histopathological changes in the anterior segment 24 h after Daclizumab and/or endotoxin treatment, stained with HE.
Numerous inflammatory cells (arrows) were observed to infiltrate the extravascular uveal tissue in the endotoxin-treated eyes (B), whereas a
significant reduction was observed when Daclizumab was also injected (C). No inflammatory cells were observed in either the Control (A) or
Daclizumab (D) groups. Bars represent 250 mm.
doi:10.1371/journal.pone.0090216.g002
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simultaneous Daclizumab administration (p#0.05 vs. E group, and
p.0.05 vs. the C and D groups) for both the parameters studied.
Similarly, endotoxin induced a 2-fold significant increase in
lipid peroxidation MDA (p#0.05 vs. the C and D groups;
Figure 3C), whereas simultaneous Daclizumab administration
prevented increased lipid peroxidation because the MDA concen-
tration returned to the control values (p#0.05 vs. the E group, and
p.0.05 vs. the C and D groups).
Daclizumab lessens Th1 lymphocytes-related mediators
and increases IL-6 cytokine values after endotoxin
treatment
Systemic endotoxin treatment induced significant increases in
the aqueous humor levels of a wide variety of inflammatory
mediators, including all the cytokines measured (p#0.05 vs. the C
and D groups; Table 2), with increases of between 3- and 500-fold
in the control values. However, the simultaneous endotoxin and
Daclizumab administration did not significantly vary most of
cytokine values in relation to endotoxin group ones (p.0.05 vs. the
E Group in Table 2).
Interestingly, Th1 lymphocytes-related cytokines, such as IL-2
(Interleukin-2) and IFN-c (Interferon-c), which increased the
control values after endotoxin administration by between 8- and
76-fold (Table 2), presented a significant reduction when
Daclizumab was administered along with endotoxin (p#0.05 vs.
E Group), thus preventing the aforementioned endotoxin-induced
increases. Furthermore, the cytokines related to monocytes (IL-1b,
IL-6, TNF-a) displayed -all of them- a tendency to increase when
Daclizumab was administered along with endotoxin. Interestingly,
IL-6 cytokine showed a significant and great increase (p#0.05 vs. E
Group) in these conditions. Nevertheless, the cytokines related to
Th2 lymphocytes (IL-4, IL-10) did not significantly alter when
Daclizumab was administered along with endotoxin (p.0.05 vs. E
Group; Table 2).
Daclizumab increases some of the macrophages related
chemokines after LPS induction
Similarly to cytokines, endotoxin treatment induced significant
increases in the concentration of all the chemokines studied in
aqueous humors (p#0.05 vs. the C and E groups; Table 3), with
increases of between 20- and 3000-fold in the control values. The
effect of Daclizumab on endotoxin-stimulated chemokines was
heterogeneous, so it induced no significant changes in most of the
chemokines studied in relation to the E group (p.0.05 vs. E
Group; Table 3). However, some related macrophages chemo-
kines, such as MIP-2, MIP-3a and GRO/KC, displayed
significant increases (p#0.05 vs. E Group; Table 3).
Discussion
Diverse studies have explored varied cytokine profiles in
different forms of uveitis, including EIU [10,11]. So, there are
numerous data which indicate that cytokines and chemokines play
a crucial role in the uveitis development, which not only regulate
the nature of immune responses [11,32], but have been detected in
Figure 3. Effect of Daclizumab on endotoxin-induced oxidative stress in rat eyes. Glutathione peroxidase activity (A), glutathione (B) and
malondialdehyde (C) concentrations were measured in the eye homogenates of the different study groups. Each value represents the mean 6 SE.
*p#0.05 vs. the Control and Daclizumab groups, and #p#0.05 the Endotoxin group.
doi:10.1371/journal.pone.0090216.g003
Table 2. Cytokine concentration in the aqueous humors of the different study groups.
Control Daclizumab Endotoxin Endotoxin+Daclizumab
IL-1a 35.165.1 33.468.9 76.3618.8* 74.6610.2*
IL-1b 4.960.9 5.362.1 918.66243.4* 1319.36313.9*
IL-2 9.860.3 9.760.6 731.66213.2* 245.3699.3*#
IL-4 94.162.1 93.663.8 293.6635.6* 323.3647.1*
IL-6 10.461.2 12.865.9 634.36260.2* 6085.161233.6*#
IL-10 4.161.0 3.762.9 102.2620.9* 80.7613.4*
TNF-a 7.562.8 7.261.5 151.8624.1* 213.7647.5*
INF-c 11.660.5 11.961.0 99.3614.3* 28.1610.8#
GM-CSF 154.9619.2 162.0623.1 1097.36287.6* 1213.26381.3*
All the values are expressed as the mean 6 SE, and are expressed in pg/ml of aqueous humor, *p#0.05 vs. C and D; # p#0.05 E+D vs. E.
doi:10.1371/journal.pone.0090216.t002
Daclizumab in Experimental Uveitis
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ocular fluids or tissues in inflamed eyes reaching a maximum
24 hours after LPS injection [33]. Thus, an elevated expression of
cytokines, such as tumor necrosis factor alpha (TNFa), interferon-
c (INFc), interleukin-6 (IL-6), Interleukin-1 (IL-1) and Interleukin-
2 (IL-2), has been observed concomitantly with maximum EIU
[9,34–35]. Moreover, Th1 activation seems to be predominant in
EIU model, but with concomitant Th2 participation [1].
Our results are consistent with these previous studies because we
found several overexpressed cytokines and chemokines in our
experimental uveitis model (Tables 2 and 3). Similarly, they
indicate that cellular infiltration and protein leakage into the
anterior chamber of rat eyes reach high levels at 24 h after LPS
injection. Thus, we found that Th1 lymphocytes-related cytokines
(IFNc, IL-2) increased in endotoxin-treated animals when
compared to control ones. Besides, the cytokines related to other
inflammatory mediators, such as the Th2 lymphocytes ones (IL-4,
IL-6, IL-10), or the macrophages ones (IL-1b, IL-6, TNF-a) also
exhibited high levels in them.
Interleukin-2 is a pleiotropic cytokine that drives T-cell growth,
augments NK cytolytic activity, induces the differentiation of
Tregs and mediates activation-induced cell death. It’s known that
Interleukin-2 plays an important role in the regulation of the
expression of IL-2 receptors and the synthesis of IFNc by T-
lymphocytes. Hence, previous studies have indicated that IL-2 can
promote IFNc production [36] and that the production of IFNc
expression is cell-cycle dependent [37].
Daclizumab prevents binding of IL-2 to its high-affinity receptor
and subsequent signaling. McDyer et al. [38] suggested that it has
a major effect on IFNc production by T-cells. Specifically,
Daclizumab inhibited the IFNc production by activated human
peripheral blood mononuclear cells through its impact on both the
IL-12-dependent and IL-12- independent pathways. Furthermore,
it has been suggested that the inhibitory activity of Daclizumab is
probably due to a direct effect of IL-2 on CD40L expression [39],
a protein member of the TNF superfamily molecules that is
primarily expressed in activated T-cells. So CD40L/CD40
interactions on antigen-presenting cells play an important role in
promoting T-cell activation and Th1 differentiation. CD40L is
also expressed at a higher frequency and for a sustained period in
polarized Th1 CD4+T-cell cultures in relation to their Th2
counterpart [39].
IL-2 also interferes with IL-6-dependent signaling events,
including downregulation of expression of the IL-6 receptor [40].
All in all, our results are consistent with these previous studies.
So, Daclizumab administration along with endotoxin reduced the
Th1 lymphocytes-related cytokines levels, such as IL-2 and IFNc,
by approximately 60–70%. However, the cytokines related to
Th2 lymphocytes (IL-4, IL-10) maintained high levels when
Daclizumab was administered along with endotoxin. On the other
hand, some of the cytokines related to monocytes and macro-
phages, such as TNFa, IL-6, IL-1a and IL-1b maintained high
concentration levels under the same conditions and even exhibited
an increasing tendency in their values (p.0.05 vs. E Group).
Moreover, one of them, IL-6, showed a great and significant
increase (p#0.05 vs. E Group).
Oxidative stress is also suggested to be pathogenic in inducing
inflammation in the eye [41]. Hence, the presence of reactive
oxygen species (ROS) exerts their toxic effects on neighboring
tissues, which involves an important event for the perpetuation of
intraocular inflammation, and simultaneously weakens the tissue’s
own antioxidant defense system.
ROS react non-specifically and rapidly with biomolecules,
including DNA, proteins, lipids and carbohydrates, and various
research works have elucidated roles for ROS in causing
molecular damage, such as DNA mutations, lipid peroxidation
and protein oxidation [41–43].
In the present study, we have measured the different parameters
related to oxidative stress in eye homogenates from rats 24 h after
endotoxin and Daclizumab treatment. Administration of Dacli-
zumab markedly increased intracellular glutathione (GSH), an
abundant natural thiol antioxidant and co-substrate for detoxifi-
cation enzymes like glutathione peroxidase (GSH-Px). Simulta-
neously, it also increased the levels of GSH-Px, a selenium-
containing enzyme that reacts with GSH molecules to regulate
lipid peroxidation. Finally, increased endotoxin-induced lipid
peroxidation was also shown by the malonyldialdehyde concen-
tration levels, a product of fatty acid peroxidation. Lipid
peroxidation products such as MDA may inhibit different enzymes
like GSH-Px in a concentration-dependent manner [44,45]. Thus,
after endotoxin and Daclizumab treatment, high MDA concen-
tration levels from endotoxin-induced rat eyes returned to the
control values. This antioxidant protective effect of Daclizumab
may be attributed to several of the observed Daclizumab effects in
our study. So and firstly, several studies have shown that IL-6 is
redox-regulated and can maintain a protective function in organs
subjected to oxidative stress. IL-6 may induce apoptosis of
neutrophils and hence contribute to neutrophil clearance [46].
Acute inflammation is characterized by an initial infiltration of
neutrophils, which is then replaced by monocytes and T cells in
order to prevent increased tissue damage from the accumulation of
neutrophil-secreted proteases and reactive oxygen species at the
site of inflammation. Upon infiltration to the site of inflammation,
neutrophils produce soluble IL6 receptor (sIL6R) by proteolytic
cleavage of the membrane bound form (mIL6R). Proteolytic
processing of the IL-6R from invading neutrophils subsequently
may drive IL-6 transsignaling in resident tissue cells, leading to a
Table 3. Chemokine concentration in the aqueous humors of the different study groups.
Control Daclizumab Endotoxin Endotoxin+Daclizumab
MIP-1a 1.261.1 1.560.4 1131.46181.1* 1225.36211.2*
MIP-2 13.862.7 12.3612.8 376.46114.2* 1202.16168.5*#
MIP-3a 3.863.1 3.162.7 9898.662257.6* 23344.664318.9*#
GRO/KC 68.2612.4 58.3629.7 4981.96933.1* 14641.563268.7*#
RANTES 6.962.2 5.361.7 967.46392.5* 912.86341.6*
MCP-1 118.7644.1 109.2621.3 123923.7643862.3* 152662.3653798.8*
Fractalkine 49.4611.3 36.1616.3 714.8697.3* 819.26189.3*
All the values are expressed as the mean 6 SE, and are expressed in pg/ml of aqueous humor, *p#0.05 vs. C and D; # p#0.05 E+D vs. E.
doi:10.1371/journal.pone.0090216.t003
Daclizumab in Experimental Uveitis
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90216
switch from neutrophil to monocyte recruitment by enhancing
mainly monocyte-attracting chemokines. IL-2 down regulates the
expression of the IL-6 receptor [40]. So it’s feasible than
Daclizumab upregulates IL-6 receptor expression. And, in this
way, during acute inflammation, the high level observed of IL-6
cytokine after Daclizumab treatment may favor the resolution of
the neutrophilic infiltrate. The finding that IL-6 induces neutro-
phil apoptosis further supports the notion that IL-6 substantially
contributes to the resolution of acute neutrophil infiltration [47].
Besides its role in attracting monocytes, IL-6 transsignaling has
been shown to skew monocyte differentiation towards macro-
phages by upregulating M-CSF receptor expression.
Moreover, recently Wruck et al. [48] have suggested a possible
role of IL-6 in oxidative stress defense. Nrf2 is a redox-sensitive
transcription factor which provides cytoprotection against electro-
philic and oxidative stress and is the most potent activator of
antioxidant response element-dependent transcription. These
authors showed that Nrf2 is a potent activator of IL-6 gene
transcription in vivo.
Then again, when Daclizumab was administered along with
endotoxin, IFN-c presented a significant reduction. IFN-c is the
most important trigger for the formation and release of ROS [49].
IFN-c is of prime importance in the development of oxidative
stress for antimicrobial and anti-tumoral defense within the cell-
mediated immune response. Thus, IFN-c is the prototypic
example of a positive regulator of nitric oxide production by
inducible nitric-oxide synthase [50,51]. Furthermore, IFNc is the
predominant cytokine implicated in the induction of indoleamine
2,3-dioxygenase, the main inducible and rate-limiting enzyme for
the catabolism of the amino acid tryptophan through the
kynurenine pathway. The interrelationships between indoleamine
2,3-dioxygenase and nitric-oxide synthase in macrophages or glial
cells are well known, as are the potential interactions with neurons
by means of N-methyl-D-aspartate (NMDA)-receptor-induced
nitric oxide formation [52].
Our previous work and that of others [35,41,53–55] demon-
strate that antioxidants may inhibit tissue damage caused by
inflammatory reactions through ROS regulation. Therefore, the
prevention of several inflammatory diseases, or diseases in which
inflammation has been found to play an important role in disease
pathogenesis and progression, could effectively be achieved by
using antioxidants.
The effect of Daclizumab on endotoxin-stimulated chemokines
was heterogeneous, since it induced no significant changes in most
of the chemokines studied as compared to the endotoxin group in
this acute model. The major role of chemokines is to act as a
chemoattractant to guide the migration of cells, which can be
produced by endothelial cells in response to cytokines, such as
TNF-a and IL-1 [11]. So, high levels were reached in some
studied chemokines under the same conditions.
All in all, some related M1 macrophages chemokines (MIP-2,
MIP-3a, GRO/KC) displayed relevant increases (p#0.05 vs. E
Group). MIP-2 is secreted by monocytes and macrophages, and is
chemotactic for polymorphonuclear leukocytes and hematopoietic
stem cells. MIP-3a is strongly chemotactic for lymphocytes and
weakly attracts neutrophils. MIP-3a expression has been observed
to be dependent on IL-6 amplifier activation [56]. GRO/KC is
expressed by macrophages, neutrophils and epithelial cells and
recently some authors [57] have suggested that this chemokine
presents any kind of protective role.
Tregs, which constitute approximately 10% of peripheral CD4+
T-cells, suppress immune system activation and maintain immune
homeostasis and tolerance to self-antigens [58]. Tregs require IL-2
for survival, so they consume, but do not produce, IL-2 and other
cytokines that promote growth and/or survival [59]. Furthermore,
Tregs promote the induction of alternatively (M2) activated
monocytes/macrophages [60]. Additionally, induction of regula-
tory T-cells by macrophages is dependent on ROS production
[61] and IL-6 inhibits TGF-beta-induced Treg differentiation
[62]. Consequently in our acute EIU model, it is possible that
Daclizumab partially acts as an agent for Treg modulation, so it
indirectly and modestly promotes the activity of classical M1
macrophages. Indeed, an increased in the different levels of
cytokines and chemokines linked to M1 macrophages activation,
such as TNFa (p.0.05 vs. E Group), MIP-2, MIP-3a, GRO/KC
and IL-6 (p#0.05 vs. E Group), would be in accordance with this
point.
Finally, in addition to the histologic preservation of ocular
structures, treatment with Daclizumab is associated with a
diminished accumulation of protein in aqueous humors, but not
inflammatory cell infiltration, similarly to the manifestations of the
beneficial effects of Daclizumab treatment in this inflammation
model.
Conclusions
At 24 h post-administration, Daclizumab treatment in EIU
reduced Th1 lymphocytes-related cytokines Interleukin-2 and
Interferon gamma by around 60–70% and was seen to play a
protective role in endotoxin-induced oxidative stress. It is feasible
to believe that this antioxidant protective effect of Daclizumab
may be related to several of the observed Daclizumab overcomes
in our study, including IL-6 cytokine regulatory assets and
significant reduction of INFc cytokine, a very important trigger
for the formation and release of ROS. Daclizumab treatment also
significantly reduced the uveal histopathological grading and the
protein concentration in aqueous humors, but not the cellular
infiltration.
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